Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
13.33
+0.24 (1.83%)
Nov 25, 2025, 4:00 PM EST - Market closed
Pulse Biosciences Revenue
Pulse Biosciences had revenue of $86.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $86.00K.
Revenue (ttm)
$86.00K
Revenue Growth
n/a
P/S Ratio
10,503.97
Revenue / Employee
$1,147
Employees
75
Market Cap
903.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 700.00K | -718.00K | -50.63% |
| Dec 31, 2021 | 1.42M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PLSE News
- 4 days ago - Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 19 days ago - Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences - Business Wire
- 20 days ago - Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study - Business Wire
- 4 weeks ago - Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025 - Business Wire
- 6 weeks ago - Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
- 7 weeks ago - Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire